Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Coudron, P. E.
Right arrow Articles by Archer, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coudron, P. E.
Right arrow Articles by Archer, G. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1987) 20, 505-511
© 1987 The British Society for Antimicrobial Chemotherapy

research-article

In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis

Philip E. Coudrona,b, J. Linda Johnstonc and Gordon L. Archerc

aLaboratory Services, McGuire Veterans Administration Medical Center Richmond, Virginia 23249, U.S.A. bDepartment of Pathology, Medical College of Virginia Richmond, Virginia 23249, U.S.A. cDepartment of Medicine, Medical College of Virginia Richmond, Virginia 23249, U.S.A.

accepted 4 April 1987

Corresponding author: Philip Coudron, Laboratory Services/113 McGuire VA Medical Center, 1201 Broad Rock Blvd, Richmond, Virginia 23249, U.S.A.

The antibacterial activity of LY146032, a new cyclic polypeptide, was compared with that of vancomycin against 163 isolates of methicillin-susceptible and methicillin-resistant Staphylococcus aureus and S. epidermidis. The MICs of LY 146032 and vancomycin for 90% of the isolates were 10 mg/l and 2.0—4.0 mg/l, respectively. Interpretative guidelines for 15 µg and 30 µg LY146032 discs could not be established because all isolates tested were susceptible to LY146032, on the basis of achievable serum levels. With one exception, MBC to MIC ratios of LY146032 and vancomycin were ≤ 2. Inoculum size had minimal effect on ratios. In time-kill studies, both drugs were 99.9% bactericidal at 6 h for four isolates at concentrations four times the MBC or less. No change in LY146032 activity was observed between isogenic pairs that were resistant to other antibiotics. Thus, LY146032 was very active in vitro against all staphylococcal isolates.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
K. L. LaPlante and M. J. Rybak
Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model
Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4665 - 4672.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
N. Safdar, D. Andes, and W. A. Craig
In Vivo Pharmacodynamic Activity of Daptomycin
Antimicrob. Agents Chemother., January 1, 2004; 48(1): 63 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Bemer, M.-E. Juvin, A. Bryskier, and H. Drugeon
In Vitro Activities of a New Lipopeptide, HMR 1043, against Susceptible and Resistant Gram-Positive Isolates
Antimicrob. Agents Chemother., September 1, 2003; 47(9): 3025 - 3029.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.